Track ALZN and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Alzamend Neuro Inc
3480 Peachtree Road NE, Atlanta, GA, United States, 30326
IPO
2021
Employees
4
Industry
Biotechnology
Sector
Healthcare
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q2 20260+1
1
Q4 202510-10
0
Q3 20259-9
0
3-quarter cumulative
19 sells1 buys
Analyst Ratings
1 analysts covering
Hold100%recommend hold
Buy
0
Hold
1
Sell
0